創世紀(300083.SZ):國家制造業基金以5億元投資入股深圳創世紀 已完成工商變更登記
格隆匯 1 月 18日丨創世紀(300083.SZ)公佈,公司控股子公司近日完成了引入國家制造業轉型升級基金股份有限公司(“國家制造業基金”)股權投資的工商變更登記並收到合計5億元投資款。
之前公吿披露,公司控股子公司深圳創世紀機械有限公司(“深圳創世紀”)經營的數控機牀等高端智能裝備業務是公司大力發展的核心主業,當前發展態勢良好、產品競爭力持續增強。國家制造業基金基於對數控機牀產業的戰略佈局及對公司數控機牀業務未來發展前景的充分認可,擬以人民幣5億元投資入股深圳創世紀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.